eBook

The Future of Coverage and Payment for Personalized Medicine Diagnostics

July 10, 2014

The past decade has seen incredible progress for the scope and impact of personalized medicine. Just ten years ago, tamoxifen and trastuzumab were among the few drugs that were routinely paired with a companion diagnostic test. Today, it seems that the FDA approves new precision-targeted therapeutics nearly every month, and the medical development pipeline includes hundreds of targeted therapies to come.  Impressive as this is, drugs targeted using combination diagnostic tests are not the only channel through which personalized medicine can become a reality. Genetic tests are increasingly available to diagnose both children and adults with difficult clinical presentations, such as metabolic and mitochondrial diseases. Non-invasive ultrasensitive genomic prenatal testing for trisomy disorders such as Down’s syndrome is also rapidly replacing traditional amniocentesis methods, and amazingly sophisticated cartridge-based kits running on platforms the size of a laser printer can now provide molecular identification of both viral and bacterial diseases.

Download the full content of The Future of Coverage and Payment for Personalized Medicine Diagnostics (.pdf)